Abstract
Chronic kidney disease has become a major public health problem worldwide mainly as a consequence of the emerging epidemic of hypertension, diabetes, and obesity. It is currently estimated that nearly 15% of the general population has some degree of renal damage, a figure that reaches 50% in at-risk subgroups. Renin-angiotensin-aldosterone system (RAAS) inhibitors represent the agents of choice to control hypertension and reduce urinary albumin excretion, thereby delaying renal function deterioration. Greater blockade of the RAAS either by the combined use of multiple drugs or by supramaximal doses of single agents may provide greater renal protection. Furthermore, it has been proposed especially in the presence of proteinuria. However, at this time there is insufficient evidence to routinely recommend this therapeutic approach in patients with chronic kidney disease. The present article examines the currently available evidence and practical implications of pharmacological disruption of RAAS activity for renal protection.
Keywords: Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, antihypertensive treatment, chronic kidney disease, hypertension, progression, proteinuria, renin-angiotensin-aldosterone system, diabetes, urinary albumin
Current Pharmaceutical Design
Title: RAAS Inhibition and Renal Protection
Volume: 18 Issue: 7
Author(s): Leoncini Giovanna, Viazzi Francesca and Pontremoli Roberto
Affiliation:
Keywords: Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, antihypertensive treatment, chronic kidney disease, hypertension, progression, proteinuria, renin-angiotensin-aldosterone system, diabetes, urinary albumin
Abstract: Chronic kidney disease has become a major public health problem worldwide mainly as a consequence of the emerging epidemic of hypertension, diabetes, and obesity. It is currently estimated that nearly 15% of the general population has some degree of renal damage, a figure that reaches 50% in at-risk subgroups. Renin-angiotensin-aldosterone system (RAAS) inhibitors represent the agents of choice to control hypertension and reduce urinary albumin excretion, thereby delaying renal function deterioration. Greater blockade of the RAAS either by the combined use of multiple drugs or by supramaximal doses of single agents may provide greater renal protection. Furthermore, it has been proposed especially in the presence of proteinuria. However, at this time there is insufficient evidence to routinely recommend this therapeutic approach in patients with chronic kidney disease. The present article examines the currently available evidence and practical implications of pharmacological disruption of RAAS activity for renal protection.
Export Options
About this article
Cite this article as:
Giovanna Leoncini, Francesca Viazzi and Roberto Pontremoli, RAAS Inhibition and Renal Protection, Current Pharmaceutical Design 2012; 18 (7) . https://dx.doi.org/10.2174/138161212799436520
DOI https://dx.doi.org/10.2174/138161212799436520 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Pharmacological Primer of Biased Agonism
Endocrine, Metabolic & Immune Disorders - Drug Targets Development of Patents and Clinical Trials on Regenerative Therapy: Gene Therapy
Recent Patents on Regenerative Medicine Targeting Drugs to APJ Receptor: The Prospect of Treatment of Hypertension and Other Cardiovascular Diseases
Current Drug Targets Effects of Transcutaneous Electrical Nerve Stimulation in Autonomic Nervous System of Hypertensive Patients: A Randomized Controlled Trial
Current Hypertension Reviews Gastroprotective Role of Glucocorticoids During NSAID-induced Gastropathy
Current Pharmaceutical Design Basic Mechanisms in Atherosclerosis: The Role of Calcium
Medicinal Chemistry Lone Atrial Fibrillation- A Diagnosis of Exclusion
Current Pharmaceutical Design Biomarkers in Atrial Fibrillation and Heart Failure
Current Medicinal Chemistry The New Adipose Tissue and Adipocytokines
Current Diabetes Reviews Waist-to-Hip Ratio (WHR) is Conversely Correlated to LAMP-2 Gene Expression Level: A Predictor for Lysosomal Lipid Entrance System
Current Nutrition & Food Science Role of Vasa Vasorum in Arterial Disease: A Re-emerging Factor
Current Cardiology Reviews Incretins and Lipid Metabolism
Current Medicinal Chemistry Body Mass Index in Midlife and Risk of Alzheimer Disease and Vascular Dementia
Current Alzheimer Research Lifestyle Modification for Masked Hypertension
Current Hypertension Reviews Smad3-Mediated Signals Showing Similarities and Differences Between Epithelial and Mesenchymal Cells in Human Chronic Liver Diseases
Current Enzyme Inhibition Mitochondrion as a Selective Target for the Treatment of Atherosclerosis: Role of Mitochondrial DNA Mutations and Defective Mitophagy in the Pathogenesis of Atherosclerosis and Chronic Inflammation
Current Neuropharmacology The Treatment of Cardiovascular Disease Continuum: Focus on Pharmacologic Management and RAS Blockade
Current Clinical Pharmacology Imidazoline Receptor Agonists for Managing Hypertension May Hold Promise for Treatment of Intracerebral Hemorrhage
Current Molecular Medicine L-Arginine Transport in Disease
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Pharmacological Strategies Against Glucocorticoid-mediated Brain Damage During Chronic Disorders
Recent Patents on CNS Drug Discovery (Discontinued)